Q&A
Nature Biotechnology 27, 971 - 972 (2009)
doi:10.1038/nbt1109-971
Steve Reed
Charlotte Schubert1
- Charlotte Schubert is the Washington, DC, correspondent for Nature Medicine
Abstract
Steve Reed believes the organization he has founded has the potential to radically increase the developing world's access to vaccines for neglected diseases. The efforts of the Seattle-based Infectious Disease Research Institute (IDRI), which operates as a not-for-profit biotech company, may start to pay off during the H1N1 'swine' flu pandemic. IDRI developed an adjuvant to boost the effectiveness and supplies of flu vaccines and is making the technology available to vaccine manufacturers in developing nations. Charlotte Schubert talks to Reed about how IDRI, a 90-person operation with a $19 million annual budget, could have such a big impact.
